Form 4: Vigil Neuroscience Director Suzanne Bruhn Receives Stock Option Grant

Director Suzanne Bruhn received a stock option grant from Vigil Neuroscience in lieu of cash compensation.

Summary

• Suzanne Louise Bruhn, a director of Vigil Neuroscience, Inc., received a stock option grant on March 1, 2024.
• The grant is for 24,073 shares of common stock at an exercise price of $3.39 per share.
• The options vest in four equal quarterly installments, starting March 31, 2024.
• The grant was awarded in lieu of cash compensation under the Issuer's Non-Employee Director Compensation Policy.
• The options expire on March 1, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice. The sentiment is neutral to slightly positive as it aligns director interests with shareholders.

Positives

• The stock option grant aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service on the board.

Industry Context

Stock options are a common form of compensation for directors, especially in biotech companies, to align their interests with shareholders and conserve cash.

Comparison to Industry Standards

• Director compensation packages vary widely across the biotechnology industry, but equity grants are a standard component.
• Comparing the size and vesting schedule of this grant to those of directors at similar-stage companies (e.g., those with a market capitalization comparable to Vigil Neuroscience) would provide a benchmark for assessing its competitiveness.
• Companies like Denali Therapeutics or Biohaven Pharmaceuticals, at similar stages of development, could be used as benchmarks for director compensation.

Stakeholder Impact

• The stock option grant could have a slightly dilutive effect on existing shareholders.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates